Premier Health Reports FY2022 Second Quarter Results

Premier Health Reports FY2022 Second Quarter Results

Premier Health of America Inc. (TSXV: PHA ) (the " Corporation "), a leading Canadian Healthtech company, announces it has filed its Condensed Interim Consolidated Financial Statements and Management Discussion and Analysis for its second quarter ended March 31, 2022.

Summary

  • The Corporation had revenues of $17.6M for the 3-month period compared to $17.0M for the same period in FY2021, representing a 3.4% increase mainly attributable to organic growth over the period.
  • The 24.7% gross margin for the quarter was close to the Corporation's 25% target.
  • EBITDA ( 1) for the quarter was $0.5M compared to $1.6M for the same period in FY2021.
  • Net income was -$0.8M compared to $0.3M for the same period in FY2021.

"We invested in our capacity to manage a wider geographical footprint" Said Martin Legault, CEO of Premier Health. "We believe these investments made upstream of contemplated acquisitions will facilitate integration and leverage operations in other provinces."

Second Quarter 2022 Results Highlights

March 31, 2022
(3 months)
March 31, 2021
(3 months)
March 31, 2022
(6 months)
March 31, 2021
(6 months)
Revenues $ 17,583,869 $ 17,003,358 $ 35,999,588 $ 30,363,667
From last period +3.4% +18.6%
Gross margin $ 4,335,299 $ 4,110,981 $ 8,755,848 $ 7,348,473
From last period +5.5% +19.2%
EBITDA (1) $ 466,798 $ 1, 582,256 $ 1,952 ,448 $ 2,900,975
From last period - 70.5% -32.7%
Net Income -$ 770,594 $ 338,508 -$ 459,305 $ 772,452
-327.6% -159.5%

(1) Adjusted EBITDA before non-recurring items

Business Highlights

  • The Corporation provided 227,748 hours of services during the quarter.
  • Revenues were slightly below budget due to Omicron variant related absenteeism and a variation in Premier Soin's unit business mix.
  • EBITDA was impacted by an increase in administrative expenses including an increase in management and technology expenses, higher than expected transport division maintenance costs, and acquisition expenses related to Canadian Health Care Agency.
  • The Corporation completed the acquisition of Canadian Health Care Agency on April 19 which is expected to add approximately $24M in annual turnover going forward.

Healthcare workforce solutions

During the second quarter, our Premier Soin business unit experienced a revenue contraction of 8% while Code Bleu's business unit revenue remained stable. The two subsidiaries offer similar services across the province of Quebec with different pricing strategy and resource profiles that sometimes lead to positive or negative revenue generation discrepancies. The decrease in revenue at Premier Soin was mainly caused by a lower demand for longer term replacement periods and a higher demand for short-term daily shifts. This business mix often results in a higher turnover rate and, by extension, a higher risk of not being able to fulfill every request for resources on short notice due to personnel availability. We believe this temporary impact is related to an adjustment period in the receding pandemic. We already experienced a shift from this situation in April but still expect a certain level of volatility in the near future. The Nordik business unit continued its organic growth steadily during the quarter with an increased deployment of resources in Northern Ontario, Northern Quebec, and James Bay. During the quarter, Premier Soin Nordik signed contractual arrangements with 6 additional hospitals. This follows the five contracts that were signed earlier in the first quarter in Northern Ontario.

Non-ambulatory transport services

The Corporation is still experimenting supply chain issues, which resulted in new vehicle deliveries being further postponed. The first 3 new transport units which delivery was postponed to March 2022 are now scheduled to be delivered only at the end of the third quarter. This resulted in higher-than-expected maintenance costs that are impacting EBTDA margins and net income.

About Premier Health

Premier Health is a leading Canadian Healthtech company that provides a comprehensive range of outsourced services solutions for healthcare needs to governments, corporations, and individuals. Premier Health uses its proprietary PSweb platform to lead the healthcare services sector digital transformation to provide patients with faster, cheaper and more accessible care services.

Non-GAAP Measures

Earnings before interest, taxes, depreciation and amortization ("EBITDA"), is calculated as the net profit (loss), before non-recurring items excluding acquisition and transaction costs, non-cash expenses (including loss from disposal of assets, impairments, amortization and depreciation), interest expense, net of interest income and income tax expense.

For Further Information Please Contact:

Mr. Jean-Robert Pronovost
Vice-President, Corporate Development
Premier Health of America Inc.
jrpronovost@premierhealth.ca / 1 800 231 9916

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

This press release contains forward-looking information based on current expectations. Statements about the date of trading of the Corporation's common shares on the Exchange and final regulatory approvals, among others, are forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Corporation assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. These factors and others are more fully discussed in the filings of the Corporation with Canadian securities regulatory authorities available at www.sedar.com.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

PHA:CA
The Conversation (0)
Premier Health Announces TSXV Approval of Normal Course Issuer Bid

Premier Health Announces TSXV Approval of Normal Course Issuer Bid

Premier Health of America Inc. (TSXV: PHA) (the " Corporation " or " Premier Health "), a leading Canadian Healthtech company, announced today that the TSX Venture Exchange (" TSXV ") has accepted the Corporation's application for its normal course issuer bid (the " NCIB ") for a portion of its outstanding common shares (" Common Shares ") as appropriate opportunities arise from time to time. The Corporation's NCIB will be made in accordance with the requirements of the TSXV and applicable securities laws.

Pursuant to the NCIB, Premier Health may repurchase up to a maximum of 1,428,571 Common Shares representing approximately a value of $500,000 at the current market price and 7% of its public float, where the aggregate public float as at November 14, 2022, was 19,664,860 Common Shares. Purchases under the NCIB may be made through the facilities of the TSXV, based on the prevailing market price at the time of acquisition. The NCIB will be funded using existing cash resources and any Common Shares purchased under the NCIB will be cancelled.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Premier Health Announces CFO Transition

Premier Health Announces CFO Transition

Premier Health of America Inc. (TSXV: PHA) (the " Corporation " or " Premier Health "), a leading Canadian Healthtech company, today announced that it is proceeding with a transition of the CFO functions and appoints Simon Belval as Interim Chief Financial Officer, effective immediately.

Simon Belval is a seasoned professional that has demonstrated strong abilities and leadership in finance and accounting functions including IFRS reporting, tax planning, financing, and risk management in different environments. He has held several leadership roles in the technology and fintech sectors and has developed over the years an expertise in managing strategic initiatives and special situations. He started his career as an external auditor and later acted as senior financial analyst for major organizations in Eastern Canada. Simon is a member of the Ordre des comptables professionnels agrées du Québec (CPA) and a Chartered Financial Analyst (CFA).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Premier Health Reports FY2022 Third Quarter Results

Premier Health Reports FY2022 Third Quarter Results

Premier Health of America Inc. (TSXV: PHA ) (the " Corporation "), a leading Canadian Healthtech company, announces it has filed its Condensed Interim Consolidated Financial Statements and Management Discussion and Analysis for its third quarter ended June 30, 2022.

Summary

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Premier Health of America

Premier Health Announces the Appointment of Giovanni Garay as Ontario General Manager

Premier Health of America Inc. (TSXV: PHA) (the " Corporation " or " Premier Health "), a leading Canadian Healthtech company, announces the appointment of Giovanni Garay as Ontario General Manager, effective immediately.

"We are very excited to have Giovanni join Premier Health. His hiring follows our recent acquisition in Ontario, and he will be an important member of the Corporation's senior leadership team," said Martin Legault, Chief Executive Officer. "Giovanni's experience with large organisations will benefit Premier Health as we continue to expand our footprint in the province." he added.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Premier Health Announces Grant of Options and Deferred Share Units

Premier Health Announces Grant of Options and Deferred Share Units

Premier Health of America Inc. (TSXV: PHA ) (" Premier Health " or the " Corporation ") announces the grant of 1,090,000 stock options to certain officers and employees of the Corporation. These stock options are granted in accordance with the terms of the stock option plan of the Corporation. All options fully vest on September 30, 2022, and each option entitles the holder thereof to purchase one (1) common share of the Corporation at a price of $0.80 per common share for a period of five (5) years from April 11, 2021. The Corporation also announces that it has granted an aggregate of 664,000 deferred share units (" DSUs ") to six directors of the Corporation. The DSUs are payable in common shares of the Corporation upon the holder ceasing to be a director of the Corporation.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic: Americans Favor Quality Over Quantity in Pursuit of Longevity

According to a new survey from Medtronic and Morning Consult, nearly two-thirds of U.S. adults say they'd opt for a shorter, healthier life than a longer one with health issues

Americans overwhelmingly say that when they think about longevity, it's more than just living longer - it's about living their healthiest, best lives. While most want to live to 90-well past the average U.S. life expectancy of 77.5 years-nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues. These findings, from a survey conducted by global healthcare technology leader Medtronic with Morning Consult, highlight a gap between U.S. adults' desire to live healthier years and the opportunity for more people to improve their quality of life through healthcare technology

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cardiex Limited

Cardiex Limited


Keep reading...Show less

Americans favor quality over quantity in pursuit of longevity

According to a new survey from Medtronic and Morning Consult, nearly two-thirds of U.S. adults say they'd opt for a shorter, healthier life than a longer one with health issues

Americans overwhelmingly say that when they think about longevity, it's more than just living longer—it's about living their healthiest, best lives. While most want to live to 90—well past the average U.S. life expectancy of 77.5 years—nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues. These findings, from a survey conducted by global healthcare technology leader Medtronic with Morning Consult, highlight a gap between U.S. adults' desire to live healthier years and the opportunity for more people to improve their quality of life through healthcare technology.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×